Novo Nordisk (NVO) Stock Falls 27% After FDA Warning on Unreported Semaglutide Adverse Events

Novo Nordisk (NVO) stock dropped 27% YTD after FDA warning letter cited failure to report semaglutide side effects, including three deaths and one suicide.

The post Novo Nordisk (NVO) Stock Falls 27% After FDA Warning on Unreported Semaglutide Adverse Events appeared first on Blockonomi.